TrialDiabetes2008

Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.

Paolo Monti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.